The Toll Is in the InstrumentWide moat
Intuitive Surgical (ISRG) — moat facet
The razor is $1.6 million and the blade expires on a counter Intuitive programmed itself.
Intuitive reports a figure most equipment makers would love to have and almost none do. Recurring revenue — instruments and accessories, service, and operating leases — was $8,465.3 million of $10,064.7 million in 2025, or 84%, and it has been 83% or 84% for three straight years1. The systems everyone talks about are the other sixteen percent.
The mechanism is a razor and blade, executed with unusual rigour. Instruments and accessories revenue was $6,018.9 million against roughly 3.30 million da Vinci and Ion procedures2 — about $1,825 of consumables consumed per procedure3, on a hospital that has already spent something like $1.6 million on the machine4 and cannot substitute a cheaper blade, because nothing else fits.
What makes it enforceable is stated in the 10-K in a single sentence about the instruments: "A programmed memory chip inside each instrument performs several functions that help determine how the da Vinci surgical system and instruments work together. In addition, the chip generally will not allow the instrument to be used for more than the prescribed number of procedures to help ensure that its performance meets specifications during each procedure."5 The safety rationale is real. So is the commercial consequence: the useful life of the consumable is a number Intuitive sets, in firmware.
The third recurring leg is service, $1,572.1 million and growing 20%, billed against an installed base of about 11,710 da Vinci systems. Service revenue scales with the base rather than with placements, which is why it grows through a soft capital year — and it is the reason a placement is worth far more than its selling price.
The vulnerability in the arrangement is the same firmware that enforces it. In April 2024 the FDA cleared an extension of the number of uses of the Ion catheter from five to eight, and European certification followed in February 20256. That is a regulator, not a competitor, reducing the number of catheters sold per hundred procedures by nearly two-fifths. It happened to a small franchise. It could happen to a large one.
What tests this facet is recurring revenue as a share of the total, 84%. Rising while procedures grow is the machine working exactly as designed. Rising because systems revenue collapsed would mean something else entirely.
The mechanism is intact and the company is choosing to relax it. The Extended Use Program, announced with the second quarter of 2026 and launching in the first half of 2027, raises the number of permitted uses on select EndoWrist instruments; the CFO declined to say whether volume and mix would offset the lost revenue per procedure. Nothing external forced this.
The blade, not the razor. It is larger than systems and service combined and it scales with operations rather than with capital budgets. The Extended Use Program is a deliberate reduction in the rate this line earns per procedure from 2027.
Source: Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 ↗- ReportedRecurring revenue — instruments and accessories, service, and operating leases — was $8,465.3 million of $10,064.7 million in 2025, or 84%, and it has been 83% or 84% for three straight years.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
- Moat Explorer calcInstruments and accessories revenue was $6,018.9 million against roughly 3.30 million da Vinci and Ion procedures — about $1,825 of consumables consumed per procedure, on a hospital that has already spent something like $1.6 million on the...Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
- Moat Explorer calcInstruments and accessories revenue was $6,018.9 million against roughly 3.30 million da Vinci and Ion procedures — about $1,825 of consumables consumed per procedure, on a hospital that has already spent something like $1.6 million on the...Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
- Moat Explorer calcInstruments and accessories revenue was $6,018.9 million against roughly 3.30 million da Vinci and Ion procedures — about $1,825 of consumables consumed per procedure, on a hospital that has already spent something like $1.6 million on the...Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
- ReportedIn addition, the chip generally will not allow the instrument to be used for more than the prescribed number of procedures to help ensure that its performance meets specifications during each procedure." The safety rationale is real.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedIn April 2024 the FDA cleared an extension of the number of uses of the Ion catheter from five to eight, and European certification followed in February 2025.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗